Stockreport

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Unicycive Therapeutics, Inc.  (UNCY) 
PDF LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patie [Read more]